Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy

Autor:	Toos Daemen, Joyce M Lubbers, Hans W. Nijman, Oana Draghiciu
Rok vydání:	2014
Předmět:	CD62L L-selectin TUMOR-BEARING MICE MDSCs myeloid-derived suppressor cells STAT3 signal transducer and activator of transcription 3 medicine.medical_treatment ARG1 arginase-1 ATRA all-trans retinoic acid PDE-5 phosphodiesterase type 5 Review IMCs immature myeloid cells HNSCC head and neck squamous cell carcinoma law.invention APCs antigen presenting cells CARCINOMA PATIENTS iNOS2 inducible nitric oxid synthase 2 law GM-CSF/CSF2 granulocyte monocyte colony stimulating factor ANTITUMOR IMMUNITY GSH glutathione TGFβ transforming growth factor β Immunology and Allergy Cytotoxic T cell JAK2 Janus kinase 2 IN-VIVO TCR T cell receptor gemcitabine IL-1β interleukin 1 β NSAID nonsteroidal anti-inflammatory drugs c-kit Mast/stem cell growth factor receptor all-trans retinoic acid TNFα tumor necrosis factor α IL-6 interleukin 6 mRCC metastatic renal cell carcinoma CCL2 chemokine (C-C motif) ligand 2 Oncology VEGFR vascular endothelial growth factor receptor Tregs regulatory T cells CDDO-Me bardoxolone methyl ESTABLISHED TUMORS DCs dendritic cells WITHANIA-SOMNIFERA medicine.drug MMPs metalloproteinases (e.g. MMP9) CTLs cytotoxic T lymphocytes ERK1/2 extracellular signal-regulated kinases FoxP3 forkhead box P3 5-Fluorouracil Immunology sunitinib therapeutic vaccination IFNγ interferon γ CANCER-PATIENTS CD8(+) T-CELLS Biology ODN oligodeoxynucleotides RNS reactive nitrogen species ROS reactive oxygen species In vivo IL-4 interleukin 4 TAMs tumor-associated macrophages medicine PGE2 prostaglandin E2 WA withaferin A GITR anti-glucocorticoid tumor necrosis factor receptor bisphosphonates CXCL15 chemokine (C-X-C motif) ligand 15 Flt3 Fms-like tyrosine kinase 3 WRE Withaferin somnifera NO nitric oxide immune suppressive mechanisms HLA human leukocyte antigen SCF stem cell factor IMMUNOSUPPRESSIVE ACTIVITY HSCs hematopoietic stem cells Cancer COX2 cyclooxygenase 2 Immunotherapy NADPH nicotinamide adenine dinucleotide phosphate-oxidase NK cells natural killer cells medicine.disease myeloid-derived suppressor cells HPV-16 human papillomavirus 16 ADAM17 metalloproteinase domain-containing protein 17 Gemcitabine Blockade TRANS-RETINOIC ACID NOHA N-hydroxy-L-Arginine NAC N-acetyl cysteine Myeloid-derived Suppressor Cell Suppressor CXCL12 chemokine (C-X-C motif) ligand 12 5-FU 5-fluorouracil HIF-1α hypoxia inducible factor 1α IL-10 interleukin 10 Myd88 myeloid differentiation primary response protein 88 ICT 3 5 7-trihydroxy-4′-emthoxy-8-(3-hydroxy-3-methylbutyl)-flavone IL-13 interleukin 13
Zdroj:	Oncoimmunology
ISSN:	2162-4011
Popis:	Myeloid-derived suppressor cells (MDSCs) contribute to tumor-mediated immune escape and negatively correlate with overall survival of cancer patients. Nowadays, a variety of methods to target MDSCs are being investigated. Based on the intervention stage of MDSCs, namely development, expansion and activation, function and turnover, these methods can be divided into: (I) prevention or differentiation to mature cells, (II) blockade of MDSC expansion and activation, (III) inhibition of MDSC suppressive activity or (IV) depletion of intratumoral MDSCs. This review describes effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d066a21e4c242e158360b8a1aa115a0 https://pubmed.ncbi.nlm.nih.gov/25949858 Zobrazit plný text záznamu